Chemoembolization for Hepatocellular Carcinoma

Seminars in Roentgenology

Volumn 46, Issue 2, 2011, Pages 105-114

  Zangan, Steven M ^a   Patel, Jay ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GELATIN SPONGE; IODINATED POPPYSEED OIL; LIVER ENZYME; MITOMYCIN; PLACEBO; POLYVINYL ALCOHOL; SORAFENIB; STARCH MICROSPHERE; YTTRIUM 90;

ARTICLE; ARTIFICIAL EMBOLISM; BILE DUCT INJURY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLECYSTITIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMORAL ARTERY; FEVER; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; LIVER ABSCESS; LIVER ANGIOGRAPHY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PATIENT SELECTION; PERCUTANEOUS DRAINAGE; PORTAL VEIN; PRIORITY JOURNAL; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; SURVIVAL RATE; TUMOR ABLATION; UPPER ABDOMINAL PAIN;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS;

EID: 79951712971     PISSN: 0037198X     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ro.2010.10.001     Document Type: Article

References (53)

1. Munoz N., Bosch F.X. Epidemiology of hepatocellular carcinoma. Neoplasms of the Liver 1989, 3-19. Springer, Tokyo. K. Okuda, K. Ishak (Eds.).
2. Muir C., Waterhouse K., Mack T., et al. Cancer Incidence in Five Continents 5 (IARC Publications. Number 88). Manual of Clinical Oncology 1987, International Agency for Research on Cancer, Lyon.
3. Bosch F.X., Munoz N. Hepatocellular carcinoma in the world: epidemiologic questions. Etiology, Pathology and Treatment of Hepatocellular Carcinoma in America: Advances in Applied Technology Series 1991, 35-54. Houston, Gulf. E. Tabor, P.R.H. Am DiBisceglie (Eds.).
4. Okuda K. Epidemiology of primary liver cancer. Primary Liver Cancer in Japan 1992, 3. Springer, Tokyo. T. Tobe (Ed.).
5. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
6. Davila J.A., Morgan R.O., Shaib Y., et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004, 127:1372-1380.
7. Bralet M.P., Regimbeau J.M., Pineau P., et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. J Hepatol 2000, 32:200-204.
8. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 365:1907-1917.
9. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatol 1998, 28:751-755.
10. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918-928.
11. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) investigators. J Hepatol 2000, 31:840-845.
12. Farinati F., Rinaldi M., Gianni S., et al. How should patients with hepatocellular carcinoma be staged?. Validation of a new prognostic system. Cancer 2000, 89:2266-2273.
13. Chevret S., Trinchet J.C., Mathieu D., et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999, 31:133-141.
14. Llovet J.M., Bru C., Bruix K. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
15. Tang Z.Y. Liver cancer. Manual of Clinical Oncology 1999, 407-424. Wiley-Liss, New York. R.E. Pollock (Ed.).
16. Primack A., Vogel C.L., Kyalwazi S.K., et al. A staging system for hepatocellular carcinoma: prognostic factors in Ugandan patients. Cancer 1975, 35:1357-1364.
17. Lai C.L., Lam K.C., Wong K.P., et al. Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer 1981, 47:2746-2755.
18. Henderson J., Sherman M., Tavill A., et al. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB 2003, 5:243-250.
19. Choti M.A., Geschwind K.F. Preoperative sequential TACE and PVE to increase respectability in the cirrhotic patient with HCC. Gastrointest Cancer Res 2008, 2:47-48.
20. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
21. Salem R., Thurston K.G. Radioembolization with yttrium-90 microspheres: a state of the art brachytherapy treatment for primary and secondary liver malignancies. II. Special topics. J Vasc Interv Radiol 2006, 17:1425-1439.
22. Ramsey D.E., Kernagis L.Y., Soulen M.C., et al. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002, 13:S211-S221.
23. Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer 1990, 66:1897-1903.
24. Nakamura H., Hashimoto T., Oi H., et al. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989, 170:783-786.
25. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in cancer. J Natl Cancer Inst 1996, 88:252-282.
26. Camma C., Schepis F., Orlando A., et al. Transarterial chemoembolization for uresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002, 224:47-54.
27. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective?. A systematic review of cohort and randomized studies. Cardiovasc Interv Radiol 2007, 30:6-25.
28. Kruskal J.B., Hlatky L., Hahnfeldt P., et al. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993, 4:741-747.
29. Ramsey D.E., Kernagis L.Y., Soulen M.C., et al. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002, 13:S211-S221.
30. Hong K., Georgiades C.S., Geschwind J.F. Technology insight: image guided therapies for hepatocellular carcinoma -intra-arterial and ablative techniques. Nat Clin Pract Oncol 2006, 3:315-354.
31. Chung J.W. Transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepato Gastroenterol 1998, 45(suppl 3):1236-1241.
32. Brown D.B., Pilgram T.K., Darcy M.D., et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005, 16:1661-1666.
33. Varela M., Real M.I., Burrel M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007, 46:474-481.
34. Malagari K., Chatzmichael K., Alexopoulou E., et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Interv Radiol 2008, 31:269-280.
35. Vit A., DePauli F., Sponza M., et al. Transarterial chemoembolization (TACE) with doxorubicin-eluting beads for the treatment of hepatocellular carcinoma. J Clin Oncol 2008, 26:237-242.
36. Reyes D.K., Vossen J.A., Kamel I.R., et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 2009, 15:526-532.
37. Grosso M., Vignali C., Quaretti P., et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Interv Radiol 2008, 31:1141-1149.
38. Malagari K., Pomoni M., Kelekis A., et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Interv Radiol 2010, 33:541-551.
39. Lammer J., Malagari K., Vogl T., et al. Prospective randomized study of doxorubicin eluting bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 2010, 33:41-52.
40. Geschwind J.F., Salem R., Carr B.I., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004, 127:S194-S205.
41. Lau W.Y., Ho S., Leung T.W., et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of yttrium-90 microspheres. Int J Radiat Oncol Biol Phys 1998, 40:583-592.
42. Cao X., He N., Sun J., et al. Hepatic radioembolization with yttrium-90 glass microspheres for treatment of primary liver cancer. Chin Med J [Engl] 1999, 112:430-432.
43. Dancey J.E., Shepherd F.A., Paul K., et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic Y-90 microsphere. J Nucl Med 2000, 41:1673-1681.
44. Kulik L.M., Atassi B., van Holsbeeck L., et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006, 94:572-586.
45. Sangro B., Bilbao J.I., Boan J., et al. Radioembolization using Y-90 resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006, 66:792-800.
46. Vente M.A., Wondergem M., van der Tweel I., et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured metaanalysis. Eur Radiol 2009, 19:951-959.
47. Salem R., Lewandowski R.L., Mulcahy M.F., et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long term outcomes. Gastroenterology 2010, 138:52-64.
48. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
49. Chan A.O., Yuen M.F., Hui C.K., et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002, 94:1747-1752.
50. Song S.Y., Chung J.W., Han J.K., et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 2001, 12:313-320.
51. Kim H.K., Chung Y.H., Song B.C., et al. Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 2001, 32:423-427.
52. Brown D.B., Chapman W.C., Cook R.D., et al. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. AJR Am J Roentgenol 2008, 190:608-615.
53. Bruix J., Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of Hepatocellular Carcinoma. J Hepatol 2005, 42:1208-1236.